BRPI0414979A - preparação sólida - Google Patents

preparação sólida

Info

Publication number
BRPI0414979A
BRPI0414979A BRPI0414979-3A BRPI0414979A BRPI0414979A BR PI0414979 A BRPI0414979 A BR PI0414979A BR PI0414979 A BRPI0414979 A BR PI0414979A BR PI0414979 A BRPI0414979 A BR PI0414979A
Authority
BR
Brazil
Prior art keywords
solid preparation
insulin
secretagogue
sensitizer
insulin sensitizer
Prior art date
Application number
BRPI0414979-3A
Other languages
English (en)
Inventor
Kazuhiro Doken
Tetsuya Kawano
Hiroyoshi Koyama
Naoru Hamaguchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34543966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0414979A publication Critical patent/BRPI0414979A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PREPARAçãO SóLIDA". Uma preparação sólida útil como um agente de tratamento do diabete ou semelhante, e excelente nas propriedades de dissolução de um sensibilizador insulínico e um secretagogo insulínico, a qual compreende um sensibilizador insulínico, um secretagogo insulínico e um éster de ácido graxo de polioxietileno sorbitano, é fornecida.
BRPI0414979-3A 2003-10-31 2004-10-21 preparação sólida BRPI0414979A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003371679 2003-10-31
PCT/JP2004/015958 WO2005041962A1 (en) 2003-10-31 2004-10-21 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester

Publications (1)

Publication Number Publication Date
BRPI0414979A true BRPI0414979A (pt) 2006-11-21

Family

ID=34543966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414979-3A BRPI0414979A (pt) 2003-10-31 2004-10-21 preparação sólida

Country Status (28)

Country Link
US (1) US7700128B2 (pt)
EP (1) EP1677792B1 (pt)
KR (2) KR100952090B1 (pt)
CN (1) CN1874774B (pt)
AR (1) AR046210A1 (pt)
AU (1) AU2004285354B2 (pt)
BR (1) BRPI0414979A (pt)
CA (1) CA2540225C (pt)
CY (1) CY1117176T1 (pt)
DK (1) DK1677792T3 (pt)
ES (1) ES2556244T3 (pt)
GE (1) GEP20084570B (pt)
HR (1) HRP20151447T1 (pt)
HU (1) HUE028576T2 (pt)
IL (1) IL174201A (pt)
JO (1) JO3106B1 (pt)
MA (1) MA28116A1 (pt)
MX (1) MXPA06004639A (pt)
NO (1) NO340294B1 (pt)
NZ (1) NZ546337A (pt)
PE (1) PE20050923A1 (pt)
PL (1) PL1677792T3 (pt)
PT (1) PT1677792E (pt)
RU (1) RU2359661C2 (pt)
SI (1) SI1677792T1 (pt)
TW (1) TWI339586B (pt)
WO (1) WO2005041962A1 (pt)
ZA (1) ZA200602056B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034999A2 (en) * 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
ZA200805147B (en) * 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
EP2033643A4 (en) 2006-06-27 2013-01-02 Daiichi Sankyo Co Ltd COMPRESSED PREPARATION
RS51592B (sr) * 2007-02-01 2011-08-31 Takeda Pharmaceutical Company Limited Čvrsti preparat koji sadrži alogliptin i pioglitazon
IS8660A (is) * 2007-07-02 2009-01-03 Actavis Group Ptc Ehf. Gliklasíð lyfjasamsetning
EP2190417A2 (en) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
US20100256196A1 (en) 2008-12-04 2010-10-07 Ikfe Biomarkers for Atherosclerosis
WO2010067207A1 (en) 2008-12-11 2010-06-17 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
US20100209350A1 (en) 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
WO2010079428A2 (en) 2009-01-07 2010-07-15 Ikfe Gmbh Biomarkers for appetite regulation
WO2010107519A1 (en) * 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US9675603B2 (en) * 2010-09-21 2017-06-13 Intekrin Therapeutics, Inc. Solid pharmaceutical compositions of ppary modulator
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
WO2013034174A1 (en) * 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
CN104288161A (zh) * 2014-09-19 2015-01-21 四川海思科制药有限公司 一种含吡格列酮格列美脲的药物组合物
MX386778B (es) 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
DK3804716T3 (da) 2018-05-31 2025-03-03 Hua Medicine Shanghai Ltd Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5865213A (ja) * 1981-10-13 1983-04-18 Tokai Kapuseru Kk ｄｌ−２−（４，８，１２−トリメチルトリデシル）−２，５，７，８−テトラメチル−６−クロマニルニコチネ−ト軟カプセル剤
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
JP2764274B2 (ja) * 1988-03-28 1998-06-11 株式会社ミドリ十字 医薬組成物
DE69426570T2 (de) 1993-11-03 2001-08-23 Isomed, Inc. Mizelleförmige feinteilige pharmazeutische zusammensetzungen
HU212428B (en) * 1994-05-13 1996-06-28 Egyt Gyogyszervegyeszeti Gyar Process to prepare pharmaceutical compositions containing gemfibrozyl
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
CN1168451C (zh) * 1997-06-18 2004-09-29 史密丝克莱恩比彻姆有限公司 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
DE69819351D1 (de) * 1997-09-11 2003-12-04 Nycomed Danmark As Roskilde Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
EA007610B1 (ru) 1998-11-12 2006-12-29 Смитклайн Бичам Плс Таблетка с энтеропокрытием, обеспечивающая отсроченное высвобождение
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
CA2407149C (en) 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003281181A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation

Also Published As

Publication number Publication date
PE20050923A1 (es) 2005-12-26
ZA200602056B (en) 2007-05-30
HRP20151447T1 (hr) 2016-02-12
TW200524641A (en) 2005-08-01
RU2359661C2 (ru) 2009-06-27
KR100952090B1 (ko) 2010-04-13
CY1117176T1 (el) 2017-04-05
AR046210A1 (es) 2005-11-30
CA2540225A1 (en) 2005-05-12
US20060223870A1 (en) 2006-10-05
RU2006118786A (ru) 2007-12-10
MXPA06004639A (es) 2006-06-27
WO2005041962A1 (en) 2005-05-12
JO3106B1 (ar) 2017-09-20
PT1677792E (pt) 2016-02-09
AU2004285354A1 (en) 2005-05-12
NZ546337A (en) 2009-03-31
US7700128B2 (en) 2010-04-20
MA28116A1 (fr) 2006-08-01
CA2540225C (en) 2012-03-06
NO340294B1 (no) 2017-03-27
IL174201A (en) 2011-04-28
GEP20084570B (en) 2008-12-25
NO20062515L (no) 2006-07-31
CN1874774B (zh) 2011-04-13
KR20100012105A (ko) 2010-02-05
EP1677792B1 (en) 2015-11-18
HUE028576T2 (en) 2016-12-28
CN1874774A (zh) 2006-12-06
AU2004285354B2 (en) 2009-09-17
DK1677792T3 (en) 2015-12-14
PL1677792T3 (pl) 2016-05-31
TWI339586B (en) 2011-04-01
EP1677792A1 (en) 2006-07-12
KR20060061383A (ko) 2006-06-07
IL174201A0 (en) 2006-08-01
SI1677792T1 (sl) 2016-02-29
ES2556244T3 (es) 2016-01-14

Similar Documents

Publication Publication Date Title
BRPI0414979A (pt) preparação sólida
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
GB0213612D0 (en) Organic compounds
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
WO2002028999A3 (en) Gene expression profiles in granulocytic cells
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
SE0001899D0 (sv) New compounds
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
DK1572127T3 (da) Enzymbehandling af fødevarer til cøliaki
BR0215052A (pt) Composições acaricidas e métodos
WO2005043967A8 (en) Z-axis assembly of medical device programmer
DE60215866D1 (de) Medikament, enthaltend cyanidin-3-glykosid als wirkstoff gegen fettsucht und diabetes
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
BRPI0510259A (pt) formulação cosmética ou dermatológica transparente
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
WO2004052294A3 (en) Compositions and methods related to lipid:emodin formulations
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
NO20050247L (no) Lavmolekylaert oversulfatert polysakkarid
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/4439, 31/64, 47/26; A61P 3/10

Ipc: A61K 31/4439 (2011.01), A61K 31/64 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.